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1 |  INTRODUCTION
Hydantoin (imidazolidin- 2,4- dione) is an interesting hetero-
cyclic core of a variety of biologically active compounds, 
including those present in pharmaceutical market, for ex-
ample, anticonvulsant phenytoin (5,5- diphenylhydantoin) 
or nilutamide (5,5- dimethyl- 3- (4- nitro- 3- (trifluoromethyl)
phenyl)imidazolidine- 2,4- dione), useful in the treatment of 
prostate cancer (Raynaud, Bonne, Bouton, Lagace, & Labrie, 
1979; Raynaud et al., 1984). Furthermore, the imidazolidine- 
2,4- dione is a grateful pattern for chemical modifications (at 
position 5 and at the nitrogen atoms in the position 1 and 
3 susceptible for various alkylations), which can enrich this 
chemical structure to strengthen, extend, or profile its biolog-
ical activity. Consequently, a vast number of previously ob-
tained 5- aromatic hydantoin derivatives, with amine moieties 
at 1- or 3- positions, demonstrated wide spectrum of pharma-
cological properties, including the following: antimicrobial 
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Abstract
In order to extend knowledge about pharmacophoric features responsible for ABCB1 
inhibitory properties of imidazolidin- 2,4- dione derivatives, 1′- [4- (4- (o- methoxyphe
nyl)- piperazin- 1- yl)butyl]- 3′- methyl- spiro(fluoren- 9,5′- imidazolidine)- 2′,4′- dione 
(3) and its salt (4) with rhodanine- 3- acetic acid (RA) were prepared and investigated 
by X- ray diffraction method, as well as their efflux modulating effects in cancer cells 
(mouse T- lymphoma), cytotoxic and antiproliferative activities were evaluated in 
vitro. The molecular geometry, intermolecular interactions, and crystal packing of 
base and acid forms of 3 were analyzed to see, if conformational changes influence 
the biological activities. The geometry of 2- methoxyphenylpiperazine and 
5- spirofluorenehydantoin moieties was compared with other crystal structures con-
taining these fragments. Our results indicated a very potent inhibitory action on 
ABCB1 pump, and significant cytotoxic and antiproliferative properties of 3 in T- 
lymphoma, even more potent in the case of multidrug resistance cells. Furthermore, 
the compound 3 converted into the salt 4 of inactive acid (RA) has maintained both, 
the efflux pump inhibitory and antiproliferative activities, showing strong synergism 
with doxorubicin. A comparison of geometry of 3 in both crystal structures (3 and 4) 
shows a significant difference in the arrangement of piperazine ring with respect to 
the aliphatic linker.
K E Y W O R D S
arylpiperazine derivative of hydantoin, crystal structure, efflux pump inhibitor, pharmacophor, 
rhodanine-3-acetic acid
   | 845ŻESŁAWSKA Et Al.
(Szymańska & Kieć- Kononowicz, 2002; Szymańska, Kieć- 
Kononowicz, Białecka, & Kasprowicz, 2002), hypotensive, 
antiarrhythmic- or/and GPCR- agents actions (Handzlik et al., 
2008, 2011). An increasing interest of potential usage of 5- , 1- 
and/or 3- substituted hydantoin derivatives in various aspects 
of cancer treatment has provided a series of active agents for 
the last decade. In this context, the 5- benzylidene- hydantoins 
inhibiting epidermal growth factor receptor (Carmi et al., 
2006), active against prostate (Khanfar & El Sayed, 2010), 
or lung cancer (Cavazzoni et al., 2008) were described. In 
contrary, results of our previous studies indicated no anti-
cancer activity, but a very high inhibitory potency against 
multidrug resistance (MDR) cancer efflux pump (ABCB1) 
for both, the 5- aryl and 5- arylidene, derivatives of hydantoin 
that also contained an arylpiperazine fragment at position 
1 or 3 (Spengler et al., 2010, 2011; Żesławska et al., 2016). 
Especially, potent efflux pump inhibitory (EPI) action, found 
for the 5,5- diphenylhydantoin arylpiperazine derivatives con-
taining rotable phenyl moieties (BS-1, Figure 1a), seemed to 
be a sufficient reason to investigate also their immobile ana-
logues that were obtained by introduction of the spirofluorene 
moiety at position 5 of hydantoin. A comparable analysis of 
the MDR EPI properties, evaluated in cancer T- lymphoma 
cells for both spirofluorene and diphenyl 3- ester substituted 
analogues, indicated that spiro(fluoren- 9,5′- imidazolidine)- 
2′,4′- dione derivatives (1 and 2, Figure 1b) are worthy of fur-
ther and extended considerations in the search for effective 
“adjuvants,” useful for future anticancer therapy.
Taking into account beneficial substituents at position 1 found 
for the previous potent hydantoin EPIs (BS-1, LL-9, Figure 1) 
(Spengler et al., 2010), we decided to investigate the 3- methyl- 
and 1-(2- alkoxyphenyl)piperazine derivatives in the next step.
In order to extend knowledge about this new chemical 
group of potential “adjuvants” for anticancer drugs, this 
study is focused on single and cooperative biological actions 
of one representative basic member and an appropriate acid, 
including a deeper insight into structural properties of each 
one and of their combination. In this context, we prepared 1′
- [4- (4- (o- methoxyphenyl)- piperazin- 1- yl)butyl]- 3′- methyl- 
spiro(fluoren- 9,5′- imidazolidine)- 2′,4′- dione (3) and its salt 
(4) with rhodanine- 3- acetic acid (RA; Figure 2) to determine 
their crystal and molecular structures, as well as to evalu-
ate their efflux modulating effects in cancer cells (mouse T- 
lymphoma), cytotoxic and antiproliferative activities.
The crystal structure analysis of salts consisting of 
two organic compounds is very interesting, since it allows 
the examination of molecules conformations, especially 
the search for conformational changes of ionic mole-
cules (Żesławska, Jacob, Sturzebecher, & Oleksyn, 2006; 
Żesławska, Nitek, & Handzlik, 2017; Żesławska, Nitek, 
Marona, & Waszkielewicz, 2018; Żesławska, Oleksyn, 
Fabre, & Benoit- Vical, 2014; Żesławska, Oleksyn, & 
Stadnicka, 2003; Żesławska, Sturzebecher, & Oleksyn, 
2007). The preparation of multicomponent monocrys-
tals suitable for X- ray analysis is a great challenge, 
but it is worth the effort due the deeper insight into the 
structural properties coming from X- ray analysis, which 
provides valuable information about possible conforma-
tional changes. The study of crystal structure of 4 gives 
a possibility to compare the conformational changes of 3 
under an influence of the acid molecule (RA). We ana-
lyzed the molecular geometry, intermolecular interactions, 
and crystal packing of base and acid forms of 3 in order 
to know, if conformational changes influence the biolog-
ical activities. We compared also geometries of 3 and 4 
with crystal structures of other 5- spirofluorenehydantoin 
derivatives with determined biological activities toward 
their efflux modulating and cytotoxicity effects in can-
cer cells (mouse T- lymphoma) (Żesławska et al., 2016). 
Furthermore, we carried out a search of the Cambridge 
Structural Database (CSD, Version 5.39) (Groom, Bruno, 
Lightfoot, & Ward, 2016) for 2- methoxyphenylpiperazine 
F I G U R E  1  The potent hydantoin 
efflux pump inhibitors obtained before: 
(a) the first- generation compounds—BS-1 
and LL-9 (Spengler et al., 2010) with 
beneficial substituents denoted in blue; (b) 
the second- generation fluorene compounds 
with ester substituent at N3 atom (Żesławska 
et al., 2016) [Colour figure can be viewed at 
wileyonlinelibrary.com]
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and 5- spirofluorenehydantoin moieties in order to compare 
conformations in the current crystal structures to other 
crystal structures containing these fragments, which were 
determined earlier.
2 |  METHODS AND MATERIALS
2.1 | Synthesis
Reagents were manufactured by Alfa Aesar (Karlsruhe, 
Germany) or Sigma- Aldrich (Darmstadt, Germany). Reaction 
progress was verified using thin layer chromatography (TLC), 
which was carried out on 0.2 mm Merck silica gel 60 F254 
plates. Spots were visualized by UV light. Melting points 
(mp) were determined using MEL- TEMP II apparatus and are 
uncorrected. The 1H NMR spectra were obtained on a Varian 
Mercury- VX 300 Mz spectrometer in DMSO- d6. Chemical 
shifts in 1H NMR spectra were reported in parts per million 
(ppm) on the δ scale using the solvent signal as an internal 
standard. Data are reported as follows: chemical shift, multi-
plicity (s, singlet; br.s., broad singlet; d, doublet; t, triplet; m, 
multiplet, def., deformed), coupling constant J in Hertz (Hz), 
number of protons, proton’s position (Flu—fluorene, Ar—
phenyl at piperazine, Pp—piperazine). IR spectra were re-
corded on a Jasco FT/IR- 410 apparatus using KBr pellets and 
are reported in cm−1. Elemental analyses were within ±0.4% 
of the theoretical values unless stated otherwise. Synthesis of 
compound 5 is described elsewhere (Żesławska et al., 2016).
2.1.1 | Synthesis of 1′- methylspiro[fluorene- 
9,4′- imidazolidine]- 2′,5′- dione (6)
Spiro[fluorene- 9,4′- imidazolidine]- 2′,5′- dione 1 (60 mmol) 
was dissolved and refluxed in ca. 240 mL of sodium 
ethanolate. After 15 min, methyl iodide (66 mmol) in 24 mL 
of absolute ethanol was added to reaction mixture. The mix-
ture was refluxed for 4 hr. After cooling to room temperature, 
the precipitated product (2) was separated and used without 
further purification. Yellow solid, mp 239°C, yield: 61%, 
C16H12N2O2 (MW: 264.28), Rf(I):0.26. 1H- NMR [DMSO- d6] 
δ: 3.01 (s, 3H, CH3), 7.32–7.37 (m, 2H, Ar- 2,7- H), 7.46–7.51 
(m, 4H, Ar- 1,3,6,8- H), 7.88 (d, J = 7.43 Hz, 2H, Ar- 4,5- H), 
8.87 (s, 1H, NH).
2.1.2 | Synthesis of 3′- (4- bromobutyl)- 1′- 
methylspiro[fluorene- 9,4′- imidazolidine]- 2′,5′- 
dione (7)
A mixture of the 1′- methylspiro[fluorene- 9,4′- imidazolidi
ne]- 2′,5′- dione (30 mmol), TEBA (3.96 mmol) and potas-
sium carbonate (87 mmol) in acetone were stirred for 30 min 
in room temperature. Then, 1,4- dibromobutane (40 mmol) 
in acetone was added and the reaction mixture was stirred 
for 96 hr. Afterward, the inorganic precipitate was filtered 
off and discarded. The remaining liquor was evaporated 
and obtained solid was crystallized from absolute ethanol. 
Creamy solid, mp 126°C, yield: 83%, C20H19BrN2O2 (MW: 
399.28), Rf(I):0.40. 1H- NMR (DMSO- d6) δ (ppm): 1.04 (q, 
J = 7.40 Hz, 2H, Br–CH2–CH2), 1.52 (q, J = 7.00 Hz, 2H, 
N1–CH2–CH2), 2.86 (t, J = 7.00 Hz, 2H, N1–CH2), 3.03 (s, 
3H, N3–CH3), 3.20 (t, J = 6.50 Hz, 2H, Br–CH2), 7.31–7.37 
(tdef, 2H, Ar- 2,7- H), 7.45–7.53 (m, 4H, Ar- 1,3,6,8- H), 7.90–
7.93 (ddef, 2H, Ar- 4,5- H).
2.1.3 | Synthesis of 1′- [4- (4- (o- 
methoxyphenyl)- piperazin- 1- yl)butyl]- 3′- 
methyl- spiro(fluoren- 9,5′- imid- azolidine)- 2′,4′- 
dione (3)
The commercially available 1- (2- methoxyphenyl)pipera-
zine (5 mmol, 0.96 g), K2CO3 (2.0 g) and acetone (25 ml) 
were stirred for 30 min. Then, a solution of 1′- (4- bromo
butyl)- 3- methyl- spiro(fluorene- 9,5′- imidazolidine)- 2′,4′
- dione 5 (5 mmol, 2.00 g) in acetone (15 ml) was added. 
The mixture was maintained at reflux for 6 hr, stirred at 
room temperature for next 15 hr. The precipitate was fil-
trated off. The filtrate was concentrated to constant weight. 
The crude residue was purified by crystallization with 
MeOH to give a yellow precipitate of 3. Yield 80%; m.p. 
135–136°C. Anal. Calcd. for C31H34N4O3 (1): C, 72.92; 
H, 6.71; N, 10.97; found: C, 72.85; H, 6.77; N, 10.91. 
1H- NMR (300 MHz, DMSO- d6) δ (ppm): 0.96–1.06 (q, 
J = 7.18 Hz, 2H, Pp- CH2–CH2), 1.16–1.21 (qdef, 2H, N1–
CH2–CH2), 1.93–1.98 (t, J = 7.05 Hz, 2H, Pp- CH2), 2.27 
(br.s, 4H, Pp- 2,6- H), 2.79 (br.s, 4H, Pp- 3,5- H), 2.88–2.92 
(t, J = 7.18 Hz, N1–CH2), 3.03 (s, 3H, N–CH3), 3.73 (s, 
3H, O–CH3), 6.81–6.92 (m, 4H, Ar–H), 7.32–7.37 (tdef, 2H, 
F I G U R E  2  Molecular diagrams of investigated compounds
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Flu- 2,7- H), 7.47–7.53 (tdef, 4H, Flu- 1,3,6,8- H), 7.90–7.93 
(ddef, 2H, Flu- 4,5- H). IR (cm−1): 3,451 (N–H), 2,943 (C–H; 
Ar), 2,814 (C–H; Aliph), 1,768 (C=O; 2), 1,704 (C=O; 4), 
1,592 (C=C; Ar).
2.2 | Crystallography
Crystals of 3 suitable for X- ray diffraction analysis were 
obtained from n- butyl acetate by slow evaporation of the 
solvent at room temperature. The RA was synthesized ac-
cording to the three- steps procedure described previously 
(Tejchman, Skórska- Stania, & Żesławska, 2016). The salt 
(4) of RA with 3 was obtained by dissolving both com-
pounds in 1:1 molar ratio in hot propan- 2- ol. Crystals ap-
peared after 3 weeks.
Diffraction data for single crystal of 3 were collected 
at 100 K using the Bruker–Nonius Kappa CCD four cir-
cle diffractometer equipped with a Mo (0.71069 Å) Kα 
radiation source. Diffraction data for 4 were collected at 
130 K on Oxford Diffraction SuperNova four circle dif-
fractometer, equipped with a Mo (0.71069 Å) Kα radia-
tion source, graphite monochromator and Oxford CryoJet 
system for measurements at low temperature. The phase 
problem was solved by direct methods using SIR- 2014 
(Burla et al., 2015). All non- hydrogen atoms were refined 
anisotropically using weighted full- matrix least- squares 
on F2. All H atoms bonded to C atoms were placed geo-
metrically in idealized positions and were refined using 
a riding model. The H atom attached to N2 atom in 4 
was identified in difference Fourier. Refinement and fur-
ther calculations were carried out using SHELXL- 2014 
(Sheldrick, 2015). For molecular graphics, ORTEP 
(Farrugia, 2012) and MERCURY (Macrae et al., 2006) 
programs were used.
Compound 3: C31H34N4O3, Mr = 510.62, crystal 
size = 0.45 × 0.27 × 0.23 mm3, triclinic, space group 
P – 1, a = 10.3380(5) Å, b = 11.4320(5) Å, c = 12.7650(6) Å, 
α = 92.978(3)°, β = 111.976(3)°, γ = 105.089(3)°, 
V = 1331.8(1) Å3, Z = 2, T = 100(2) K, 10,071 reflec-
tions collected, 6,051 unique reflections (Rint = 0.0280), 
R1 = 0.0485, wR2 = 0.1246 [I > 2σ(I)].
Compound 4: C31H35N4O+3 ⋅C5H4NO3S−2  , Mr = 701.84, 
crystal size = 0.43 × 0.33 × 0.03 mm3, monoclinic, 
space group P21/c, a = 26.3451(4) Å, b = 10.9060(2) Å, 
c = 12.1116(2) Å, β = 100.869(2)°, V = 3417.5(1) Å3, Z = 4, 
T = 130(2) K, 47,115 reflections collected, 8,237 unique 
reflections (Rint = 0.0394), R1 = 0.0421, wR2 = 0.0939 
[I > 2σ(I)].
CCDC 1886047–1886048 contain the supplementary 
crystallographic data. These data can be obtained free of 
charge from The Cambridge Crystallographic Data Centre 
via www.ccdc.cam.ac.uk/data_request/cif.
2.3 | Biological assays
2.3.1 | Cell lines
The L5178Y mouse T- lymphoma cells (PAR; ECACC Cat. 
No. 87111908, obtained from FDA, Silver Spring, MD, USA) 
were transfected with pHa MDR1/A retrovirus, as previously 
described by Cornwell, Pastan, and Gottesman (1987). The 
ABCB1- expressing cell line L5178Y (MDR) was selected by 
culturing the infected cells with colchicine. L5178Y (parent) 
mouse T- lymphoma cells and the L5178Y human ABCB1 
transfected subline were cultured in McCoy’s 5A medium 
(Sigma- Aldrich) supplemented with 10% heat- inactivated 
horse serum (Sigma- Aldrich), 200 mM l- glutamine (Sigma- 
Aldrich) and a penicillin streptomycin (Sigma- Aldrich) mix-
ture in concentrations of 100 U/L and 10 mg/L, respectively.
2.3.2 | Rhodamine 123 accumulation assay 
by flow cytometry
The inhibition of ABCB1 by the tested compounds was 
evaluated using flow cytometry measuring the retention 
of rhodamine 123 (R123; Sigma- Aldrich) by ABCB1 (P- 
glycoprotein) in MDR mouse T- lymphoma cells over-
expressing the ABCB1 protein. The percentage of mean 
fluorescence intensity was calculated for the treated MDR 
cells as compared with the parental (PAR) untreated cells. 
Verapamil (Sigma- Aldrich) was used as positive control. A 
fluorescence activity ratio (FAR) was calculated based on the 
following equation which relates the measured fluorescence 
values (Żesławska et al., 2016):
2.3.3 | Assay for cytotoxic and 
antiproliferative effect
The cytotoxicity and antiproliferative assays on T- lymphoma 
cells were performed according to the protocol described 
previously (Poljarević et al., 2018; Żesławska et al., 2018). 
Inhibition of the cell growth was determined according to the 
formula:
where IC50 is defined as the inhibitory dose that reduces 
the growth of the cells exposed to the compound by 50%. 
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2.3.4 | Checkerboard combination assay
A checkerboard microplate method was applied to study 
the effect of drug interactions between the tested com-
pounds and the chemotherapeutic drug, doxorubicin (Teva 
Pharmaceuticals), thus to determine the combination index 
(CI) for the compounds (Magyari et al., 2018).
On MDR mouse T- lymphoma cells CI values at 50% of 
the growth inhibition dose (ED50), were determined using 
CompuSyn software (www.combosyn.com; ComboSyn, 
Inc., Paramus, NJ, USA) to plot four to five data points to 
each ratio. CI values were calculated by means of the median- 
effect equation, where CI < 1, CI = 1, or CI > 1 represent 
synergism, additive effect (or no interaction), or antagonism, 
respectively (Chou, 2006).
3 |  RESULTS
3.1 | Chemistry
Compound (3) was synthesized in four- step syn-
thesis (Figure 3). In the first step (a), spiro(fluoren- 
9,5′- imidazolidine)- 2′,4′- dione (5) as a product of 
Bucherer–Berg condensation of the commercially available 
9- fluorenone with ammonium carbonate and potassium 
cyanide was obtained. Then, N- alkylation at position 3 of 
the hydantoin ring with methyl iodide; (b) was performed 
(6), followed by an alkylation with 1,4- dibromobutane at 
position 1 that was carried out in acetone with K2CO3 and 
TEBA as two- phase mediator; (c). In the last step; (d), the 
intermediate, 1′- (4- bromobutyl)- 3′- methyl- spiro(fluoren- 9,
5′- imidazolidine)- 2′,4′- dione (7), was used for N- alkylation 
of 1- (2- methoxyphenyl)piperazine to give white powder of 
compound (3), after crystallization with ethanol. Details 
of synthesis of intermediate 5 were described elsewhere 
(Żesławska et al., 2016).
3.2 | Crystallographic studies
Both compounds crystallize with one molecule in the asym-
metric unit, but in different space groups 3 in P – 1 and 4 in 
P21/c. An overview of asymmetric units of 1 and 2 with the 
atom numbering scheme is shown in Figure 4.
The asymmetric unit of 4 consists of one cation derived 
by protonation of 3 and one anion derived from RA. The 
protonated N atom is engaged in the charge- assisted N2+–
H2···O3a− hydrogen bond. The spirofluorene substituent is 
almost perpendicular to hydantoin ring in both structures, 
the correspondence dihedral angles are 88.19(5)° for 3 and 
86.15(5)° for 4. The conformation of 3 molecule seems to 
be mainly dependent on the flexible aliphatic chain between 
piperazine and hydantoin rings. The spacer between hydan-
toin and piperazine rings consists of four methylene groups 
and adopts bent conformation at C6 atom. Its conformation is 
similar in both crystal structures, as indicated by the torsion 
angles: N1–C6–C7–C8 = 63.85° and 61.76°, C6–C7–C8–
C9 = −179.30° and −165.43°, C7–C8–C9–N2 = 169.89° 
and 170.79° for 3 and 4, respectively. There is a significant 
difference in the arrangement of piperazine ring with respect 
to the linker (Figure 5). The torsion angles C8–C9–N2–C12 
and C8–C9–N2–C10 differ in both structures, namely, these 
values are 69.23° and −169.11° for 3 and −78.13° and 
48.62° for 4. The piperazine ring adopts chair conformation 
in both structures. The mutual orientation of piperazine and 
aromatic rings is similar. The corresponding dihedral angle 
is 51.25(7)° and 46.41(7)° for 3 and 4, respectively.
The packing of molecules in the crystal structure of 3 
is dominated by C–H···O intermolecular interactions. The 
F I G U R E  3  The synthesis route. 
Conditions: (i) KCN, (NH4)2CO3, 50% 
EtOH, 48 hr, 560°C; (ii) CH3I, EtONa, 
reflux for 3 hr; (iii) 1,4- dibromobutane, 
K2CO3, TEBA, acetone, stirring at rt for 
96 hr; (iv) K2CO3, acetone, reflux for 5 hr
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parameters of these interactions are listed in Table 1. Only ox-
ygen atoms of hydantoin ring are engaged in intermolecular 
interactions. The spirofluorene substituent of two molecules, 
related by inversion centre, is engaged in π- π interactions.
In the crystal structure of 4 different arrangements of the 
cations in comparison with 3 is observed. In this case, there 
are not observed the π–π interactions between spirofluorene 
substituents. The crystal lattice is dominated by N+–H···O−, 
C–H···N, C–H···O and C–H···S intermolecular interactions. 
Parameters of these interactions are presented in Table 2. It 
is worth noting that RA anion is involved in many hydrogen 
bonds, both as an acceptor with the use of oxygen and sulfur 
atoms, and as a donor hydrogen atoms by methylene group.
3.3 | Biological activities
Arylpiperazine derivatives of 5- spirofluorenehydantoin 
showed the capacity to inhibit an MDR efflux pump such 
as the ABCB1 (Żesławska et al., 2016). In Table 3, there 
are presented the biological activity results of 3, RA and 
the salt 4. These compounds were investigated toward 
their efflux modulating, cytotoxic, antiproliferative and 
combination effects in sensitive and resistant mouse T- 
lymphoma cells.
Compound 3 displayed efflux modulating effect, as 
well as the cytotoxic and antiproliferative effects in both 
cell lines. However, RA showed only weak antiprolifera-
tive effect in MDR cells. The investigated salt 4 possessed 
similar activity as active compound 3 in the case of efflux 
modulating and antiproliferative effects, while the cyto-
toxic activity was twice reduced. In the combination assay, 
compounds 3 and 4 showed strong synergistic effect with 
doxorubicin (Table 4).
4 |  DISCUSSION
The molecular structures of 3 and 4 were compared to 
other molecules containing 5- spirofluorenehydantoin moi-
ety with determined crystal structures. The arrangement of 
this fragment is similar to other 5- spirofluorenehydantoin 
derivatives, in which the values of the angle between the 
planes of hydantoin and spirofluorene moieties are 86.7°, 
89.7° (Żesławska et al., 2016). There is also determined 
the crystal structure of 5- spirofluorenehydantoin, in which 
this angle is 87.0° (Todorov, Nikolova, Naydenova, & 
Shivachev, 2012).
We have also analyzed the mutual orientation of pipera-
zine and aromatic rings in other crystal structures. We have 
done a search of the Cambridge Structure Database (CSD, 
Version 5.39) (Groom et al., 2016) for crystal structures 
containing o- methoxyphenyl substituent at nitrogen atom 
of piperazine ring in order to see the values of the angle 
between the planes of piperazine and aromatic rings. As 
shown in Figure 6 for 43 hits of organic compounds, the 
vast majority have value of this angle in the range from 39° 
to 48°. This orientation is related to the presence of metoxy 
group in ortho position. The oxygen atom of this group is 
engaged in a weak intramolecular interaction with the equa-
torial hydrogen atom of the piperazine ring. The obtained 
value of this angle for 4 is very frequent observed in other 
crystal structures containing 2- methoxyphenylpiperazine 
moiety deposited in the CSD, while the value for 3 is less 
frequent.
We compared obtained biological results with the re-
sults of other two spirofluorenehydantoin derivatives (1 and 
2) possessing determined crystal structures and evaluated 
F I G U R E  4  The molecular structures of (a) 3 and (b) 4 showing 
the atom numbering scheme. Displacement ellipsoids are drawn at the 
30% probability level. Dashed line indicates hydrogen bond [Colour 
figure can be viewed at wileyonlinelibrary.com]
F I G U R E  5  The overlap of the hydantoin rings in the crystal 
structure of 3 green and 4 purple. The hydrogen atoms have been 
omitted for clarity [Colour figure can be viewed at wileyonlinelibrary.
com]
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P- glycoprotein inhibition properties and cytotoxic effects 
(Żesławska et al., 2016). The biological activities results are 
listed in Table 5. These compounds differ in substituents at 
N3 and N4 atoms in comparison with 3. Both compounds (1 
and 2) were less potent than 3 and 4, displaying up to four-
fold stronger P- gp- inhibitory action than that of verapamil, 
whereas more than 15- fold of the action of verapamil was 
demonstrated by 3 and 4 in the corresponding concentration. 
The cytotoxic effect of 1 and 2 was also distinctly weaker in 
comparison with 3 and 4.
In Figure 7a, it is presented the overlap of hydantoin rings 
in 1, 2, 3 and 4 in order to see the changes in conformation of 
the same moiety in these molecules. A common part of these 
compounds is 1′- [4- (piperazin- 1- yl)butyl]- spiro(fluoren- 9,5′- 
imidazolidine- 2′,4′- dione fragment. The mutual orientation of 
spirofluorene and hydantoin moiety is the same in all mole-
cules. Differences are visible in the conformation of aliphatic 
chain, which consequently changes the distances of the pipera-
zine ring from hydantoin and aromatic ring. These differences 
are characterized by the values of torsion angles C2–N1–C6–
C7: −99.11°, 124.72°, −120.82° and −125.67°, as well as 
N1–C6–C7–C8: 54.54°, −169.29°, 61.72° and 63.96° for 1, 2, 
3 and 4, respectively. For compound 2, the values of compared 
torsion angles differ significantly in comparison with other 
three. These conformational changes cause a different spatial 
distribution of N4- substituted piperazine ring with respect to 
the 5- spirofluorenehydantoin system. Moreover, in Figure 7b, 
it is presented the superposition of all four compared struc-
tures with respect to aliphatic chain in order to see the mu-
tual spatial orientation of 5- spirofluorenehydantoin moiety 
and N4- substituted piperazine ring. Only for compound 2, the 
spirofluorene system is perpendicular to aliphatic chain, while 
for other three compounds is parallel.
It can be concluded that the presence of not active com-
pound RA did not influence significantly on biological ac-
tivities toward efflux modulating and antiproliferative effects 
of 3, and therefore, a partial change of conformation of N- 
(o- methoxyphenyl)- piperazine moiety in molecule 4 is not 
related to these activities. In contrast, a distinct influence of 
RA on the cytotoxic effects was observed. The bending and 
twisting of piperazine ring in relation to the linker seem to be 
not favorable for the cytotoxic activity.
It was postulated earlier that the presence of an aromatic 
ring in compound is important for cancer efflux pumps 
D–H···A H···A (Å) D···A (Å) D–H–A (°) Symmetry code
C15–H15···O2 2.50 3.427 (2) 167 –x + 1, –y + 1, –z + 2
C18–H18···O4 2.73 3.377 (2) 126 –x + 1, –y + 1, –z + 1
C23–H23···O4 2.51 3.348 (2) 148 –x, –y + 1, –z + 1
C29–H29···O2 2.49 3.418 (2) 167 –x, –y + 2, –z + 2
T A B L E  1  Intermolecular hydrogen- 
bonds geometry for 3
D–H···A H···A (Å) D···A (Å) D–H–A (°) Symmetry code
N2–H2···O3A 1.58 2.545 (2) 172
C5A–H5A···O2 2.29 3.150 (2) 145 x, −y + 3/2, z + 1/2
C5A–H5B···N4 2.36 3.325 (2) 164 x, y + 1, z
C6–H6A···O4 2.44 3.318 (2) 148 x, –y + 1/2, z + 1/2
C10–H10B···S1A 2.88 3.530 (2) 124 x, −y + 3/2, z + 1/2
C13–H13A···O2A 2.62 3.424 (2) 138
C13–H13B···O2A 2.52 3.426 (2) 153 x, −y + 3/2, z + 1/2
C26–H26A···O2A 2.53 3.316 (2) 137 x, y − 1, z
T A B L E  2  Intermolecular hydrogen- 




(μM) Cytotoxic effect Antiproliferative effect
2 20 PAR MDR PAR MDR
3 7.22 75.83 19.40 ± 0.13 13.25 ± 0.55 11.56 ± 0.59 6.98 ± 0.11
4 6.35 73.28 40.46 ± 1.08 28.26 ± 1.16 9.83 ± 0.78 7.05 ± 0.16
RA 0.81 0.75 >100 >100 >100 41.14 ± 1.20
Notes. Verapamil (20 μM) fluorescence activity ratio (FAR) = 4.81, DMSO (2%) FAR = 0.92.
aFAR values are calculated for the MDR mouse T- lymphoma cell line. 
T A B L E  3  The efflux modulating, 
cytotoxic, and antiproliferative effects of 3, 
4 and rhodanine- 3- acetic acid (RA) on 
L5178Y sensitive (parental [PAR]) and 
resistant (MDR) mouse T- lymphoma cells
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modulator properties, while the presence of second aromatic 
ring increased inhibition of this efflux pump (Handzlik et al., 
2012; Reis et al., 2013). The influence of other pharmacoph-
ore features, namely, positive ionizable center and hydrogen 
bond acceptor, is not very strong on this activity, but is prof-
itable (Handzlik et al., 2012).
Taking this into consideration, we analyzed the distances 
between aromatic rings and nitrogen atoms in these com-
pounds (Table 6). We have chosen the following distances: 
between the centroids of aromatic rings (Cg1, Cg2—aromatic 
rings in spirofluorene substituent, Cg3—aromatic ring at N4 
of piperazine ring), between the centroids of aromatic rings 
and nitrogen atoms (N2 and N4), as well as between nitrogen 
atoms (N1, N2 and N4).
All compounds were more active than verapamil, but the 
most active 3 is 10- fold higher active than 2. Only for com-
pound 2, the extended conformation of linker is observed, 
which increases the distance between N1 and N2, as well 
as N1 and N4 in comparison with 1, 3 and 4. Likewise, the 
increased distances between centroid (Cg2) and nitrogen 
atoms (N2, N4) are observed, while the distances between 
centroid (Cg1) and N2 and N4 atoms decreased. Although 
the extended conformation of the linker seems to be respon-
sible for weaker cancer efflux pumps activity, probably it 
is not only one factor because this compound possesses an 
T A B L E  4  Type of interaction between compounds and 
doxorubicin on multidrug- resistant (MDR) T- lymphoma cells
Compound Ratioa CI at ED50b Interaction
3 11.6:1 0.12 ± 0.1 Strong synergism
4 13.9:1 0.18 ± 0.1 Strong synergism
aData are shown as the best combination ratio between the tested compounds and 
doxorubicin. bCombination index (CI) values at the 50% growth inhibition dose 
(ED50) were determined by the CompuSyn software to plot four to five data points 
at each ratio. CI values were calculated by means of the median- effect equation, 
where CI: 0.1–0.3 represent strong synergism.
F I G U R E  6  (a) The fragment used in the search of the 
Cambridge Structural Database (CSD). (b) The distribution of angles 
between the plane containing of four C atoms of piperazine ring and 
the plane of aromatic ring for 43 hits found in the CSD containing 
2- methoxyphenylpiperazine fragment
T A B L E  5  Efflux modulating and cytotoxic effects of the 
compounds 3 and 4 on L5178Y sensitive (parental [PAR]) and 
resistant (MDR) mouse T- lymphoma cells (Żesławska et al., 2016)
Cpd
FARa IC50 (μM)
Concentration (μM) Cytotoxic effect
2 20 PAR MDR
1 21.61 70.19 53 ± 5 >100
2 1.86 24.89 59 ± 13 63 ± 9
Notes. Verapamil (20 μM) fluorescence activity ratio (FAR) = 17.59, DMSO 
(2%) FAR = 0.84.
aFAR values are calculated for the MDR mouse T- lymphoma cell line. 
F I G U R E  7  The overlap of (a) the hydantoin rings and (b) the 
aliphatic chains (C6, C7, C8 and C9 atoms) in the crystal structures 
of 1—green, 2—blue, 3—red, and 4—yellow. The hydrogen atoms 
have been omitted for clarity [Colour figure can be viewed at 
wileyonlinelibrary.com]
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acyl- heterocyclic ring, in place of desirable aromatic one, at 
piperazine moiety.
5 |  CONCLUSIONS
The studies performed allowed to find a new very potent can-
cer efflux pump inhibitor (3) that represents 3- methyl deriva-
tives of spiro(fluoren- 9,5′- imidazolidine)- 2′,4′- dione. The 
compound 3 can also be considered as potential anticancer 
agent, useful against drug- resistant cells, since the cytotoxic 
and antiproliferative properties of 3 on T- lymphoma were 
significant, and even more potent in the case of MDR cells 
if comparing to the PAR ones. Furthermore, our results in-
dicated that compound 3 converted into salt of inactive RA 
(4) has maintained both, the efflux pump inhibitory and an-
tiproliferative, activities. In particular, both forms (3 and 4) 
had a strong synergistic action with doxorubicin, used as a 
reference anticancer agent. So far, we have not enough crys-
tal structures of active aromatic hydantoin derivatives to 
uniquely determine the preferred conformation and distances 
between the pharmacophoric features responsible for their 
cancer efflux pump inhibition. However, this comprehensive 
study significantly contributed to extend knowledge in this 
field and can be useful for further considerations.
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